If we focus on innovation and sustainability, healthcare will evolve in ways that are in sync with the changing needs of patients, the economy and global politics.
The following post is excerpted from Paul Perreault’s remarks at International BioFest 2016 in Melbourne, Australia.
December 6, 2016
Healthcare statisticians tell us that the first person who will live to 150 years of age has already been born. Considering human biology and the challenges we would need to overcome, doubling our life expectancy at first seems fanciful. But with our understanding of science and the refined art of personalized medicine, 150 may be reasonable.
In fact, our understanding of human biology is expanding at an exponential rate. Ten years ago it took the world’s greatest minds 10 years to map the human genome. Now it takes one day. Even for those of us in the healthcare sector, it is virtually impossible to predict what healthcare will look like in 50 or 100 years. But there are constants to guide us.
The CSL Behring Professor Heimburger Award is helping to ensure young researchers around the world have the opportunity to bring their innovative ideas to the forefront.
October 17, 2016
We are seeing some exciting research as CSL Behring delivers on our promise to advance research and innovation through grants such as the Heimburger Award.
This is particularly important for young researchers working in clinics who often don’t have time to raise money for their research. Adding to the challenge is the fact that government funding of orphan disease research is often difficult to obtain.
That’s why we’re building for the future in Lengnau and around the world to meet growing demand and bring more therapies to more patients.
September 22, 2016 By Uwe E. Jocham
These are exciting times at CSL Behring, as we expand our infrastructure to keep pace with the increasing demand for new innovations that address unmet medical needs or enhance current treatments.
We are currently building for the future in Lengnau, Switzerland, where we are constructing a state-of-the-art recombinant manufacturing facility. The foundation stone of the new structure was laid in May. With this production site, CSL Behring is creating a new product family based on state-of-the-art technology.
The plant will manufacture and globally market three new recombinant coagulation factors: recombinant Factor IX Fusion Protein for patients with hemophilia B, recombinant Factor VIII-Single Chain to treat hemophilia A, and a recombinant Factor VIIa-Fusion Protein treat hemophilia patients with inhibitors. Continue reading →
“If we think about patients every day and do the right things for them, the rest will take care of itself.”
September 13, 2016 By Christopher Florentz
This summer’s World Federation of Hemophilia Congress got off to a fast start with CSL Behring’s coagulation team eager to meet with patients and healthcare providers and discuss their needs and how we can meet them.
The level of excitement among the CSL Behring’s team was palpable, as CSL CEO and Managing Director Paul Perreault kicked things off at the start of the Congress by reinforcing to them the importance of maintaining focus on what matters most:
“If we think about patients every day and do the right things for them, the rest will take care of itself. We began with the promise to produce much needed medicines for the people of Australia. Today we are bringing medicines to the world.”
Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring. This site is not intended as a forum for discussing CSL Behring or other companies' products. Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.